Serum Institute of India Private Ltd, 212/2, Off Soli Poonawalla Road, Hadapsar, Pune, Maharashtra 411028, India.
Viroclinics Xplore, Viroclinics Biosciences B.V. Nistelrooise Baan 3, 5374RE Schaijk, the Netherlands.
Vaccine. 2020 Sep 11;38(40):6280-6290. doi: 10.1016/j.vaccine.2020.07.043. Epub 2020 Jul 31.
During a pandemic, the availability of specific pathogen free chicken eggs is a major bottleneck for up-scaling response to the demand for influenza vaccine. This has led us to explore the use of Madin-Darby Canine Kidney (MDCK) cells for the manufacture of live attenuated influenza vaccine (LAIV) that provides production flexibility and speed. The present study reports the comparison of the immunogenicity and efficacy of two MDCK-based LAIVs against two egg-based LAIVs prepared from the same pandemic potential strains of H5 and H7 subtypes after a single dose of the vaccine followed by a challenge with a homologous wild type strain. The vaccine strains have been generated by classical method of reassortment using the A/Leningrad/134/17/57 master donor strain. Additionally, a prime-boost regimen of the MDCK-based vaccine followed by a challenge with a homologous wild type strain for H5 and H7 immunized ferrets and also a heterologous wild type strain for the H5 immunized animals was studied. No difference in the hemagglutination inhibition and virus neutralization antibody titers against the homologous virus was observed following a single dose of either egg-based or MDCK-based H5 and H7 LAIV vaccine. A second dose of MDCK-based vaccine significantly boosted antibody titers in the vaccinated animals. Both a single dose or two doses of LAIV provided complete protection from lower respiratory tract infection and resulted in a significant reduction in the virus titers recovered from the throat, nasal turbinates and lungs after challenge with the homologous wild type strain. Protection from a challenge with a heterologous strain of H5 was also observed after two doses of the MDCK-based LAIVs. This data strongly supports the use of MDCK as a substrate for the manufacture of LAIV which ensures reliable quality, safety, production flexibility, speed and breadth of protection, features that are highly critical during a pandemic.
在大流行期间,特定无病原体鸡卵的供应是扩大对流感疫苗需求的主要瓶颈。这促使我们探索使用 Madin-Darby 犬肾(MDCK)细胞来制造活减毒流感疫苗(LAIV),从而提供生产灵活性和速度。本研究报告了两种基于 MDCK 的 LAIV 与两种基于鸡蛋的 LAIV 之间的免疫原性和功效比较,这些 LAIV 是使用相同的大流行潜力 H5 和 H7 亚型的病毒株制备的,在接种一剂疫苗后进行了同源野生型菌株的挑战。疫苗株是使用 A/Leningrad/134/17/57 主供体株通过经典的重配方法产生的。此外,还研究了 MDCK 为基础的疫苗进行加强免疫后,用同源野生型病毒株对 H5 和 H7 免疫的雪貂进行挑战,以及用异源野生型病毒株对 H5 免疫的动物进行挑战的方案。接种一剂基于鸡蛋或 MDCK 的 H5 和 H7 LAIV 疫苗后,针对同源病毒的血凝抑制和病毒中和抗体滴度没有差异。接种 MDCK 为基础的疫苗的第二剂显著增强了接种动物的抗体滴度。一剂或两剂 LAIV 均可提供针对下呼吸道感染的完全保护,并在接种同源野生型病毒株后从喉咙、鼻甲骨和肺部回收的病毒滴度显著降低。两剂 MDCK 为基础的 LAIV 也可提供针对 H5 异源株的保护。这些数据强烈支持使用 MDCK 作为制造 LAIV 的基质,这确保了可靠的质量、安全性、生产灵活性、速度和保护范围,这些特征在大流行期间非常关键。